The approaching patent cliff — projected to expose as much as $300 billion in annual drug sales to loss of exclusivity by 2032 — is expected to keep pharmaceutical dealmaking steady in 2026. According to Norstella's Dan Chancellor, most acquisitions influence company performance three to five years out. Large pharma has been aware of the risk for years and has already incorporated it into portfolio strategies, but persistent growth gaps mean the deal pipeline won't slow down.
Key PDUFA dates ahead include oral azacitidine for AML (extending from MDS/CMML approval), tolebrutinib for non-relapsing SPMS, and several supplemental applications. The shift from IV to all-oral regimens remains a dominant theme across hematologic malignancies.
Despite mildly anticlimactic remission rates, analysts now believe Compass's psilocybin therapy data could clear the FDA bar — a potential landmark for psychedelic medicine. The regulatory path remains novel and closely watched by the entire mental health field.
The field's focus at Tandem 2026 shifted decisively from which antigen to target toward how cellular therapies are engineered and individualized. Three themes dominated: biomimetic receptor engineering to widen the therapeutic index (the ARTEMIS platform EB-103 achieved 100% CR in aggressive B-NHL with only grade 1–2 CRS), allogeneic CAR-T strategies demonstrating early clinical feasibility, and histology-specific dosing patterns that challenge cross-disease extrapolation. Together, these signal the beginning of a platform-driven era in cellular therapy.
The DURGA-1 phase 1b/2 trial of AZD0120 — a first-in-class BCMA/CD19 dual CAR-T with rapid manufacturing — demonstrated early and deep MRD-negative responses in heavily pretreated myeloma. The dual-target hypothesis: reduce antigen-negative relapse and target myeloma progenitor cells simultaneously.
A detargeted fusogen approach using VSV-G mutation avoids liver uptake while achieving high T-cell transduction efficiency in vivo. Four patients achieved MRD negativity — without the traditional weeks-long manufacturing process. If validated, this could democratize CAR-T access globally.
India hosted one of the world's biggest AI events this week — but it was marred by organizational chaos, security confusion, and Bill Gates pulling out amid Epstein scrutiny. Despite the drama, U.S. tech firms couldn't resist: OpenAI announced it would be the first customer of TCS's data center business, Google expanded Gemini partnerships with Indian institutions, and India formally signed the U.S.-led Pax Silica coalition for critical AI minerals. PM Modi inaugurated the event at Bharat Mandapam.
Cinematic AI-generated videos of celebrities in absurd situations have gone viral — all created with ByteDance's Seedance 2.0. The tool's quality leap raises fresh questions about deepfakes, copyright, and whether China's AI sector will self-regulate before governments force it.
The NYT examines the gap between AI hype and reality: a Boston programmer tested Codex's limits and found that while AI accelerates routine coding, complex problem-solving and system design remain firmly human. The piece argues the disruption will be gradual, not overnight.
Houston led by 16 heading into the fourth quarter. New York outscored them 33–15 in the final frame. Karl-Anthony Towns led the comeback with 25 points and 7 rebounds, OG Anunoby added 20 with 4 steals. Kevin Durant had 30 for Houston but it wasn't enough. The Knicks won the turnover battle 19–11.
Victor Wembanyama put on a complete performance as San Antonio crushed Sacramento 139–122, outscoring the Kings in all four quarters. The Spurs' winning streak is the longest in the Western Conference this season.
Phoenix trailed Orlando for most of regulation but clawed back, then Jalen Green drained a three at the buzzer in 2OT to seal it. The Suns recorded 11 steals and won the turnover battle 16–8. Desmond Bane had 34 in a losing effort.
Frau Holle hat genug: Zwischen Hitze, Dauerregen und Beschwerdebriefen übergibt sie das Wettermachen an zwei Assistenten — mit chaotischen Folgen. Sebastian Schwabs Kinderoper verhandelt den Klimawandel zwischen Sonnenschein-Dur und wütenden Wetter-Arien. Ab Mo 23.2., 10:30 Uhr.
„Ich war so beleidigt auf Gott, wie mein Opa gestorben ist." Ein kluges, witziges Stück über Glauben, Synagoge, Moschee und Elfen — in Laut- und Gebärdensprache, mit Gitarre und Querflöte. Wiederaufnahme ab Mi 25.2., 14:10 Uhr.